These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 19630066)
1. In vitro determination of the release of alendronic acid from alendronate tablets of different brands during deglutition. Lamprecht G J Pharm Sci; 2009 Oct; 98(10):3575-81. PubMed ID: 19630066 [TBL] [Abstract][Full Text] [Related]
2. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications. Dansereau RJ; Crail DJ; Perkins AC Curr Med Res Opin; 2008 Apr; 24(4):1137-45. PubMed ID: 18334082 [TBL] [Abstract][Full Text] [Related]
3. In vitro disintegration and dissolution and in vivo bioequivalence of two alendronate once-weekly formulations. Almeida S; Almeida A; Filipe A; Penedo C; Rocha A; Lainesse A; Vallée F Arzneimittelforschung; 2006; 56(2):84-9. PubMed ID: 16572922 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo equivalence studies of alendronate monosodium tablets. Roldán EJ; Quattrocchi O; Zanetti D; Piccinni E; Tessler J; Caballero LE; Lloret AP Arzneimittelforschung; 2005; 55(2):93-101. PubMed ID: 15787276 [TBL] [Abstract][Full Text] [Related]
5. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Epstein S; Cryer B; Ragi S; Zanchetta JR; Walliser J; Chow J; Johnson MA; Leyes AE Curr Med Res Opin; 2003; 19(8):781-9. PubMed ID: 14687450 [TBL] [Abstract][Full Text] [Related]
6. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931 [TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate. Shakweh M; Bravo-Osuna I; Ponchel G Eur J Pharm Sci; 2007 Aug; 31(5):262-70. PubMed ID: 17576054 [TBL] [Abstract][Full Text] [Related]
8. Conjugation of poorly absorptive drugs with mucoadhesive polymers for the improvement of oral absorption of drugs. Sakuma S; Matsumoto T; Yamashita S; Wang Y; Lu ZR J Control Release; 2007 Nov; 123(3):195-202. PubMed ID: 17888541 [TBL] [Abstract][Full Text] [Related]
9. High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. Yun MH; Kwon KI J Pharm Biomed Anal; 2006 Jan; 40(1):168-72. PubMed ID: 16095861 [TBL] [Abstract][Full Text] [Related]
10. Rapid determination of alendronate to quality evaluation of tablets by high resolution ¹H NMR spectroscopy. Xie B; Liu A; Fang X; Chen Y; Zhong H J Pharm Biomed Anal; 2014 May; 93():73-6. PubMed ID: 24215933 [TBL] [Abstract][Full Text] [Related]
11. Comment on Disintegration/dissolution profiles of copies of Fosamax (alendronate). Bolaños Díaz R Curr Med Res Opin; 2004 Jul; 20(7):1035-6; author reply 1036-7. PubMed ID: 15265248 [No Abstract] [Full Text] [Related]
12. In vitro quality evaluation of leading brands of ciprofloxacin tablets available in Bangladesh. Uddin MS; Mamun AA; Hossain MS; Asaduzzaman M; Sarwar MS; Rashid M; Herrera-Calderon O BMC Res Notes; 2017 May; 10(1):185. PubMed ID: 28558832 [TBL] [Abstract][Full Text] [Related]
15. A sensitive post-column photochemical derivatization/fluorimetric detection system for HPLC determination of bisphosphonates. Pérez-Ruiz T; Martínez-Lozano C; García-Martínez MD J Chromatogr A; 2009 Feb; 1216(9):1312-8. PubMed ID: 19150069 [TBL] [Abstract][Full Text] [Related]
16. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets. Breier AR; Paim CS; Steppe M; Schapoval EE J Pharm Pharm Sci; 2005 Aug; 8(2):289-98. PubMed ID: 16124939 [TBL] [Abstract][Full Text] [Related]
17. Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers. Simanjuntak R; Setiawati E; Yunaidi DA; Handayani LR; Setiawati A; Utami BS; Rosa TA; Sholeh AB Drug Res (Stuttg); 2014 Mar; 64(3):136-40. PubMed ID: 24002927 [TBL] [Abstract][Full Text] [Related]
19. Upper gastrointestinal tract transit times of tablet and drinkable solution formulations of alendronate: a bioequivalence and a quantitative, randomized study using video deglutition. Gómez Acotto C; Antonelli C; Flynn D; McDaid D; Roldán EJ Calcif Tissue Int; 2012 Nov; 91(5):325-34. PubMed ID: 22923328 [TBL] [Abstract][Full Text] [Related]
20. Process analytical technology to understand the disintegration behavior of alendronate sodium tablets. Xu X; Gupta A; Sayeed VA; Khan MA J Pharm Sci; 2013 May; 102(5):1513-23. PubMed ID: 23450666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]